Search

Your search keyword '"Ogino, Takashi"' showing total 576 results
Start Over Author "Ogino, Takashi"
576 results on '"Ogino, Takashi"'

2. Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry

Author

Harada, Hideyuki, Suefuji, Hiroaki, Mori, Keita, Ishikawa, Hitoshi, Nakamura, Masaki, Tokumaru, Sunao, Murakami, Masao, Ogino, Takashi, Iwata, Hiromitsu, Tatebe, Hitoshi, Kubo, Nobuteru, Waki, Takahiro, Yoshida, Daisaku, Nakamura, Masatoshi, Hashimoto, Takayuki, Araya, Masayuki, Nakajima, Mio, Nakayama, Haruhiko, Satouchi, Miyako, and Shioyama, Yoshiyuki

Published
2024
Full Text
View/download PDF

3. Inhibition of G protein-coupled receptor 68 using homoharringtonine attenuates chronic kidney disease-associated cardiac impairment

Author

Yoshida, Yuya, Fukuoka, Kohei, Sakugawa, Miyu, Kurogi, Masayuki, Hamamura, Kengo, Hamasaki, Keika, Tsurusaki, Fumiaki, Sotono, Kurumi, Nishi, Takumi, Fukuda, Taiki, Kumamoto, Taisei, Oyama, Kosuke, Ogino, Takashi, Tsuruta, Akito, Mayanagi, Kouta, Yamashita, Tomohiro, Fuchino, Hiroyuki, Kawahara, Nobuo, Yoshimatsu, Kayo, Kawakami, Hitomi, Koyanagi, Satoru, Matsunaga, Naoya, and Ohdo, Shigehiro

Published
2024
Full Text
View/download PDF

4. Proton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-institutional patients’ registration database, Proton-Net

Author

Yamazaki, Hideya, Shibuya, Kei, Kimoto, Takuya, Suzuki, Motohisa, Murakami, Masao, Terashima, Kazuki, Okimoto, Tomoaki, Iizumi, Takashi, Sakurai, Hideyuki, Wakatsuki, Masaru, Suzuki, Osamu, Katoh, Norio, Arimura, Takeshi, Ogino, Takashi, Takagi, Masaru, Araya, Masayuki, Waki, Takahiro, Matsumoto, Sae, Ogino, Hiroyuki, Fukumoto, Takumi, and Ohtsuka, Masayuki

Published
2023
Full Text
View/download PDF

5. Multi-Institutional Retrospective Analysis of the Outcomes of Proton Beam Therapy for Patients With 1 to 3 Pulmonary Oligometastases From Various Primary Cancers

Author

Aibe, Norihiro, Ogino, Hiroyuki, Teramukai, Satoshi, Yamazaki, Hideya, Iwata, Hiromitsu, Matsuo, Yoshiro, Okimoto, Tomoaki, Murakami, Masao, Suzuki, Motohisa, Arimura, Takeshi, Ogino, Takashi, Murayama, Shigeyuki, Harada, Hideyuki, Nakamura, Masaki, Akimoto, Tetsuo, and Sakurai, Hideyuki

Published
2021
Full Text
View/download PDF

7. Proton Beam Therapy for Hepatocellular Carcinoma: Multicenter Prospective Registry Study in Japan

Author

Mizumoto, Masashi, primary, Ogino, Hiroyuki, additional, Okumura, Toshiyuki, additional, Terashima, Kazuki, additional, Murakami, Masao, additional, Ogino, Takashi, additional, Tamamura, Hiroyasu, additional, Akimoto, Tetsuo, additional, Waki, Takahiro, additional, Katoh, Norio, additional, Araya, Masayuki, additional, Onoe, Tsuyoshi, additional, Takagi, Masaru, additional, Iwata, Hiromitsu, additional, Numajiri, Haruko, additional, Okimoto, Tomoaki, additional, Uchinami, Yusuke, additional, Maruo, Kazushi, additional, Shibuya, Kei, additional, and Sakurai, Hideyuki, additional

Published
2024
Full Text
View/download PDF

9. Prostaglandin F2α Affects the Cycle of Clock Gene Expression and Mouse Behavior

Author

Tsurudome, Yuya, primary, Yoshida, Yuya, additional, Hamamura, Kengo, additional, Ogino, Takashi, additional, Yasukochi, Sai, additional, Yasuo, Shinobu, additional, Iwamoto, Ayaka, additional, Yoshihara, Tatsuya, additional, Inazumi, Tomoaki, additional, Tsuchiya, Soken, additional, Takeo, Toru, additional, Nakagata, Naomi, additional, Higuchi, Shigekazu, additional, Sugimoto, Yukihiko, additional, Tsuruta, Akito, additional, Koyanagi, Satoru, additional, Matsunaga, Naoya, additional, and Ohdo, Shigehiro, additional

Published
2024
Full Text
View/download PDF

10. Patterns of proton therapy use in pediatric cancer management in 2016: An international survey

Author

Journy, Neige, Indelicato, Daniel J., Withrow, Diana R., Akimoto, Tetsuo, Alapetite, Claire, Araya, Masayuki, Chang, Andrew, Chang, John Han-Chih, Chon, Brian, Confer, Michael E., Demizu, Yusuke, Dendale, Rémi, Doyen, Jérôme, Ermoian, Ralph, Gurtner, Kristin, Hill-Kayser, Christine, Iwata, Hiromitsu, Kim, Joo-Young, Kwok, Young, Laack, Nadia N., Lee, Choonsik, Lim, Do Hoon, Loredo, Lilia, Mangona, Victor S., Mansur, David B., Murakami, Masao, Murayama, Shigeyuki, Ogino, Takashi, Ondrová, Barbora, Parikh, Rahul R., Paulino, Arnold C., Perkins, Stephanie, Ramakrishna, Naren R., Richter, Ronald, Rombi, Barbara, Shibata, Satoshi, Shimizu, Shinichi, Timmermann, Beate, Vern-Gross, Tamara, Wang, Chiachien J., Weber, Damien C., Wilkinson, John Ben, Witt Nyström, Petra, Yock, Torunn I., Kleinerman, Ruth A., and Berrington de Gonzalez, Amy

Published
2019
Full Text
View/download PDF

13. Proton Beam Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study in Japan

Author

Mizumoto, Masashi, primary, Terashima, Kazuki, additional, Makishima, Hirokazu, additional, Suzuki, Motohisa, additional, Ogino, Takashi, additional, Waki, Takahiro, additional, Iwata, Hiromitsu, additional, Tamamura, Hiroyasu, additional, Uchinami, Yusuke, additional, Akimoto, Tetsuo, additional, Okimoto, Tomoaki, additional, Iizumi, Takashi, additional, Murakami, Masao, additional, Katoh, Norio, additional, Maruo, Kazushi, additional, Shibuya, Kei, additional, and Sakurai, Hideyuki, additional

Published
2023
Full Text
View/download PDF

14. Inhibition of G0/G1 Switch 2 Ameliorates Renal Inflammation in Chronic Kidney Disease

Author

Matsunaga, Naoya, Ikeda, Eriko, Kakimoto, Keisuke, Watanabe, Miyako, Shindo, Naoya, Tsuruta, Akito, Ikeyama, Hisako, Hamamura, Kengo, Higashi, Kazuhiro, Yamashita, Tomohiro, Kondo, Hideaki, Yoshida, Yuya, Matsuda, Masaki, Ogino, Takashi, Tokushige, Kazutaka, Itcho, Kazufumi, Furuichi, Yoko, Nakao, Takaharu, Yasuda, Kaori, Doi, Atsushi, Amamoto, Toshiaki, Aramaki, Hironori, Tsuda, Makoto, Inoue, Kazuhide, Ojida, Akio, Koyanagi, Satoru, and Ohdo, Shigehiro

Published
2016
Full Text
View/download PDF

16. Proton Beam Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study in Japan.

Author

Mizumoto, Masashi, Terashima, Kazuki, Makishima, Hirokazu, Suzuki, Motohisa, Ogino, Takashi, Waki, Takahiro, Iwata, Hiromitsu, Tamamura, Hiroyasu, Uchinami, Yusuke, Akimoto, Tetsuo, Okimoto, Tomoaki, Iizumi, Takashi, Murakami, Masao, Katoh, Norio, Maruo, Kazushi, Shibuya, Kei, and Sakurai, Hideyuki

Subjects
PROTON therapy, CHOLANGIOCARCINOMA, LONGITUDINAL method, OVERALL survival, PROGRESSION-free survival
Abstract

Introduction: Intrahepatic cholangiocarcinoma (ICC) can be treated with chemotherapy in unresectable cases, but outcomes are poor. Proton beam therapy (PBT) may provide an alternative treatment and has good dose concentration that may improve local control. Methods: Fifty-nine patients who received initial PBT for ICC from May 2016 to June 2018 at nine centers were included in the study. The treatment protocol was based on the policy of the Japanese Society for Radiation Oncology. Forty patients received 72.6–76 Gy (RBE) in 20–22 fr, 13 received 74.0–76.0 Gy (RBE) in 37–38 fr, and 6 received 60–70.2 Gy (RBE) in 20–30 fr. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier analysis. Results: The 59 patients (35 men, 24 women; median age: 71 years; range: 41–91 years) had PS of 0 (n = 47), 1 (n = 10), and 2 (n = 2). Nine patients had hepatitis and all 59 cases were considered inoperable. The Child-Pugh class was A (n = 46), B (n = 7), and unknown (n = 6); the median maximum tumor diameter was 5.0 cm (range 2.0–15.2 cm); and the clinical stage was I (n = 12), II (n = 19), III (n = 10), and IV (n = 18). At the last follow-up, 17 patients were alive (median follow-up: 36.7 months; range: 24.1–49.9 months) and 42 had died. The median OS was 21.7 months (95% CI: 14.8–34.4 months). At the last follow-up, 37 cases had recurrence, including 10 with local recurrence. The median PFS was 7.5 months (95% CI: 6.1–11.3 months). In multivariable analyses, Child-Pugh class was significantly associated with OS and PFS, and Child-Pugh class and hepatitis were significantly associated with local recurrence. Four patients (6.8%) had late adverse events of grade 3 or higher. Conclusion: PBT gives favorable treatment outcomes for unresectable ICC without distant metastasis and may be particularly effective in cases with large tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry study

Author

Tatebe, Hitoshi, primary, Harada, Hideyuki, additional, Mori, Keita, additional, Iwata, Hiromitsu, additional, Akimoto, Tetsuo, additional, Murakami, Masao, additional, Waki, Takahiro, additional, Ogino, Takashi, additional, Nakamura, Masatoshi, additional, Taguchi, Hiroshi, additional, Nakayama, Haruhiko, additional, Satouchi, Miyako, additional, and Aoyama, Hidefumi, additional

Published
2023
Full Text
View/download PDF

26. A Japanese registry study and systematic review of particle therapy for renal cell carcinoma.

Author

Ishikawa, Hitoshi, Arimura, Takeshi, Maruo, Kazushi, Kawamura, Hidemasa, Toyama, Shingo, Ogino, Takashi, Okimoto, Tomoaki, Murakami, Masao, Sato, Yoshitaka, Nishioka, Kentaro, Araya, Masayuki, Ohba, Hisateru, Umehara, Kensuke, Aoyama, Hidefumi, Obara, Wataru, Azuma, Haruhito, Tsuji, Hiroshi, and Sakurai, Hideyuki

Abstract

The feasibility and efficacy of particle beam therapy (PBT) using protons or carbon ions were compared with those of photon-based stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC) via a systematic review and nationwide registry for PBT (Japanese Society for Radiation Oncology [JASTRO] particle therapy committee). Between July 2016 and May 2019, 20 patients with non-metastatic RCC who were treated at six Japanese institutes (using protons at three, using carbon ions at the other three) were registered in the nationwide database and followed up prospectively. The 20 patients comprised 15 men and had a median age of 67 (range: 57–88) years. The total radiation dose was 66–79.6 Gy (relative biological effectiveness [RBE]). Over a median follow up of 31 months, the 3-year rates of overall survival (OS) and local control (LC) were 100% and 94.4%, respectively. No grade ≥ 3 toxicities were observed. Based on a random effects model, a meta-analysis including the present results revealed 3-year OS rates after SBRT and PBT of 75.3% (95% CI: 57.3–86.6) and 94.3% (95% CI: 86.8–97.6), respectively (P  = 0.005), but the difference in LC rates between the two methods was not observed (P  = 0.63). PBT is expected to have similar if not better treatment results compared with SBRT for primary renal cancer. In particular, PBT was shown to be effective even for large RCC and could provide a therapeutic option when SBRT is not indicated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Synaptic pruning of murine adult-born neurons by microglia depends on phosphatidylserine

Author

Kurematsu, Chihiro, primary, Sawada, Masato, additional, Ohmuraya, Masaki, additional, Tanaka, Motoki, additional, Kuboyama, Kazuya, additional, Ogino, Takashi, additional, Matsumoto, Mami, additional, Oishi, Hisashi, additional, Inada, Hiroyuki, additional, Ishido, Yuri, additional, Sakakibara, Yukina, additional, Nguyen, Huy Bang, additional, Thai, Truc Quynh, additional, Kohsaka, Shinichi, additional, Ohno, Nobuhiko, additional, Yamada, Maki K., additional, Asai, Masato, additional, Sokabe, Masahiro, additional, Nabekura, Junichi, additional, Asano, Kenichi, additional, Tanaka, Masato, additional, and Sawamoto, Kazunobu, additional

Published
2022
Full Text
View/download PDF

37. Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer

Author

Nagata, Ichiro, Ogino, Takashi, Arimura, Takeshi, and Yoshiura, Takashi

Subjects
non-small-cell lung, adenocarcinoma, Japan, proton therapy, Targets and Therapy [Lung Cancer], carcinoma, ground-glass opacity, Original Research
Abstract

Ichiro Nagata,1,2 Takashi Ogino,1 Takeshi Arimura,1 Takashi Yoshiura2 1Medipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan; 2Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, JapanCorrespondence: Ichiro NagataMedipolis Proton Therapy and Research Center, 4423 Higashikata, Ibusuki, Kagoshima 891-0304, JapanTel +81 993 23 5188Fax +81 993 24 3450Email nagata-ichiro@snbl.co.jpPurpose: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical resection in these patients, this study aimed to examine the retrospective treatment outcomes of patients with GGO-type lung cancer who underwent PBT.Patients and Methods: Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 2015 were included. Patients were treated with a total dose of 66 GyE delivered in 10 fractions. Survival curves were calculated using the Kaplan–Meier method, and treatment-related adverse events (AEs) were assessed.Results: A total of 48 patients (median age: 70.9 ± 9.2 years; men: 54.2%) were analyzed, among whom 53 tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% confidence interval [CI], 79.3– 96.8%), the 3-year disease-free survival rate was 85.4% (95% CI: 71.8– 92.8%), and the 3-year local control rate among 53 tumors was 92.5% (95% CI: 81.1– 97.1%). During the 3-year follow-up period, 4 patients died, and 3 survived despite recurrence or metastasis. Common AEs were radiation pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the patients developed grade ≥ 3 treatment-related AEs.Conclusion: The results of this study suggest that PBT may be a promising alternative for patients with GGO-type lung cancer when surgical resection is not feasible, with excellent survival outcomes and tolerable treatment-related AEs.Keywords: proton therapy, carcinoma, non-small-cell lung, ground-glass opacity, adenocarcinoma, Japan

Published
2020

41. Chronic allergy to dietary ovalbumin induces lymphocyte migration to rat small intestinal mucosa that is inhibited by MAdCAM-1

Author

Ogawa, Toshiko, Miura, Soichiro, Tsuzuki, Yoshikazu, Ogino, Takashi, Teramoto, Ken, Inamura, Toshiaki, Watanabe, Chikako, Hokari, Ryota, Nagata, Hiroshi, and Ishii, Hiromasa

Subjects
Albumin -- Research, Biological sciences
Abstract

Few models have described a chronic food allergy with morphological changes in the intestinal mucosa. Here we established an ovalbumin (OVA)-induced, cell-mediated, allergic rat model and examined lymphocyte migration in the gut. Brown Norway rats were intraperitoneally sensitized to OVA and then given 10 mg OVA/day by gastric intubation for 6 wk. Lymphocyte subsets and adhesion molecules were examined immunohistochemically, and the migration of T lymphocytes to microvessels of Peyer's patches and villus mucosa was observed by using an intravital microscope. Serum OVA-specific IgG and IgE levels were increased in animals repeatedly exposed to OVA. Significant villus atrophy and increased crypt depth was accompanied by increased infiltration of T lymphocytes in the small intestinal mucosa of the group given OVA. Expression of rat mast cell protease II and of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) was also increased in these groups. The administration of anti-MAdCAM-I antibody significantly attenuated the OVA-induced changes in the mucosal architecture and in CD4 T lymphocyte infiltration. Intravital observation demonstrated that in rats with a chronic allergy, T lymphocytes significantly accumulated in villus microvessels as well as in Peyer's patches via a MAdCAM-l-dependent process. Our model of chronic food allergy revealed that lymphocyte migration was increased with MAdCAM-1 upregulation. Brown Norway rats; rat mast cell protease II; delayed type hypersensitivity; Peyer's patch; intercellular adhesion molecule-1

Published
2004

43. Spatial heterogeneity of TNF-[alpha]-induced T cell migration to colonic mucosa is mediated by MAdCAM-1 and VCAM-1

Author

Watanabe, Chikako, Miura, Soichiro, Hokari, Ryota, Teramoto, Ken, Ogino, Takashi, Komoto, Shunsuke, Hara, Yuriko, Koseki, Seiichiro, Tsuzuki, Yoshikazu, Nagata, Hiroshi, Granger, D. Neil, and Ishii, Hiromasa

Subjects
T cells -- Research, Digestive organs -- Research, Biological sciences
Abstract

Relatively little is known about how recirculation of lymphocytes through the inflamed intestinal mucosa is regulated. The aim of this study was to investigate the dynamic process of T lymphocyte-endothelial cell adhesion in TNF-[alpha]-challenged murine colonic mucosa by intravital microscopy. T lymphocytes from spleen (SPL) and intestinal lamina propria (LPL) were fluorescence labeled, and their adhesion to microvessels in the colonic mucosa was observed. In TNF-[alpha] (25 [micro]g/kg)-stimulated colonic venules, an enhanced adhesion of SPL and LPL was demonstrated, with dominant recruitment of LPLs. The magnitude of the increased LPL adhesion was more significant in the colon than in the small intestine. These T lymphocyte interactions in the colonic mucosa were significantly reduced by blocking MAbs against either mucosal addressin cell adhesion molecule-1 (MAdCAM-1), VCAM-1, [[alpha].sub.4]-integrin, or [[beta].sub.7]-integrin but not by anti-ICAM-1. Immunohistochemistry revealed significant MAdCAM-1 expression in the lamina propria and VCAM-1 expression in the submucosa of TNF-[alpha]-treated colon. Spatial heterogeneity of MAdCAM-1 and VCAM-1 activation following TNF-[alpha] challenge may promote specific T lymphocyte recruitment in the inflamed colonic mucosa. microcirculation; inflammatory bowel disease; [[alpha].sub.4]-integrin; [[beta].sub.7]-integrin; lamina proprial lymphocytes

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results